Cytokines as prognstic tool in breast carcinoma

Frontiers in Bioscience

Volumn 16, Issue 7, 2011, Pages 2515-2526

  Lv, Mingli ^a   Zhang, Xiaoping ^a   Cai, Haidong ^a   Li, Dang ^a   Wang, Jian ^a   Fu, Xingjian ^a   Yu, Fei ^a   Sun, Ming ^a   Lv, Zhongwei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast Cancer; Cytokine; ER; HER 2; Lymph Node

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; BREAST TUMOR; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 79959547258     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3869     Document Type: Article

References (36)

1. J A Pain, S R Ebbs, R P Hern, S Lowe, J W Bradbeer: Assessment of breast cancer size: a comparison of methods. Eur J Surg Oncol, 18 (1), 44-48 (1992)
2. J Fernandes: Prognostic factors in breast cancer: pathologic features that reflect behavior. Del Med J, 63 (3):167-71 (1991)
3. A L Abner, L Collins, G Peiro, A Recht, S Come, L N Shulman, B Silver, A Nixon, J R Harris and S J Schnitt: Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer, 83 (12):2502-08 (1998) (Pubitemid 29019569)
4. P R Rosen, S Groshen, P E Saigo, D W Kinne and S Hellman: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol, 7 (3):355-66□1998□
5. V Vinh-Hung, T Burzykowski, G Cserni, M Voordeckers, J Van De Steene and G Storme: Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol, 22 (3):697-704 (2003)
6. A Recht, R Gray, N E Davidson, B L Fowble, L J Solin, F J Cummings, G Falkson, H C Falkson, S GTaylor, and D C Tormey: Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol, 17 (6):1689-1700 (1997) (Pubitemid 29269237)
7. P Eifel, J A Axelson, J Costa, J Crowley, W J Curran Jr, A Deshler, S Fulton, C B Hendricks, M Kemeny, A B Kornblith, T A Louis, M Markman, R Mayer and D Roter. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst, 93 (13):978-89 (2001)
8. R K Orr: The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian metaanalysis. Ann Surg Oncol, 6 (1):109-116 (1996)
9. S Y Lee, I Hwang, Y S Park, J Gardner and J Y Ro: Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes? Int J Oncol, 36 (6):1461-1467 (2010)
10. T Cil, J Hauspy, H Kahn, S Gardner, W Melnick, Flynn and C M Holloway: Factors affecting axillary lymph node retrieval and assessment in breast cancer patients. Ann Surg Oncol, 15 (12):3361-68 (2008)
11. S Partelli, C Fernandez-Del Castillo, C Bassi, W Mantovani, S P Thayer, S Crippa, C R Ferrone, M Falconi, P Pederzoli and A L Warshaw: Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg, 251 (3):477-482 (2010)
12. J Martinkova, S J Gadher, M Hajduch and H Kovarova: Challenges in cancer research and multifaceted approaches for cancer biomarker quest. FEBS Lett, 583 (11):1772-84 (2009)
13. E F Petricoin, A M Ardekani, B A Hitt, P J Levine, V A Fusaro, S M Steinberg, G B Mills, C Simone, D A Fishman and E C Kohn: Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359 (9306):572-77 (2002) (Pubitemid 34178440)
14. F Lumachi, S M Basso and R Orlando: Cytokines, thyroid diseases and thyroid cancer. Cytokine, 50 (3):229-33 (2010)
15. M E Danko, K M Bennett, J Zhai, J R Marks, and J A Olson: Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. J Am Coll Surg, 210 (5):797-805 e791 (2010)
16. F Balkwill and A Mantovani: Inflammation and cancer: back to Virchow? Lancet, 357 (9255):539-45 (2001) (Pubitemid 32173595)
17. L M Coussens and Z Werb: Inflammation and cancer. Nature, 420 (6917):860-67 (2002) (Pubitemid 36019639)
18. A Mantovani, P Allavena, A Sica and F Balkwill: Cancerrelated inflammation. Nature, 454 (7203):436-44 (2008)
19. Z A Dehqanzada, C E Storrer, M T Hueman, R J Foley, K A Harris, Y H Jama, C D Shriver, S Ponniah and G E Peoples: Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep, 17 (3):687-94 (2007)
20. B M Nolen, J R Marks, S Ta'san, A Rand, T M Luong, Y Wang, K Blackwell and A E Lokshin: Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res, 10 (3):R45 (2008)
21. A Maccio, C Madeddu, G Gramignano, C Mulas, C Floris, D Massa, G Astara, P Chessa and G Mantovani: Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med, 88 (7):677-86 (2010)
22. O I Ahmed, A M Adel, D R Diab and N S Gobran: Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol, 13 (2):61-68 (2006).
23. P Kuvaja, A Talvensaari-Mattila, P Paakko, T Turpeenniemi-Hujanen: Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma. Hum Pathol, 37 (10):1316-23 (2006) (Pubitemid 44380276)
24. G La Rocca, I Pucci-Minafra, A Marrazzo, P Taormina and S Minafra: Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer, 90 (7):1414-21 (2004) (Pubitemid 38586271)
25. Y Lu, Z Cai, D L Galson, G Xiao, Y Liu, D E George, M F Melhem, Z Yao and J Zhang: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate, 66 (12):1311-18 (2006) (Pubitemid 44384308)
26. G Soria, N Yaal-Hahoshen, E Azenshtein, S Shina, L Leider-Trejo, L Ryvo, E Cohen-Hillel, A Shtabsky, M Ehrlich and T Meshel: Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine, 44 (1):191-200 (2008).
27. E Neumark, O Sagi-Assif, B Shalmon, A Ben-Baruch and I P Witz: Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer, 106 (6):879-86 (2003) (Pubitemid 37071666)
28. L Goldberg-Bittman, E Neumark, O Sagi-Assif, E Azenshtein, T Meshel, I P Witz and A Ben-Baruch: The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett, 92 (1-2):171-78 (2004). (Pubitemid 38470065)
29. D Datta, J A Flaxenburg, S Laxmanan, C Geehan, M Grimm, A M Waaga-Gasser, D M Briscoe and S Pal: Rasinduced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res, 66 (19):9509-18 (2006) (Pubitemid 44623649)
30. W L McGuire: Endocrine therapy of breast cancer. Annu Rev Med, 26:353-63 (1975)
31. L Skoog, S Humla, M Axelsson, M Frost, A Norman, B Nordenskjold and A Wallgren: Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy. Acta Oncol, 26 (2):95-100 (1987) (Pubitemid 17144041)
32. G Carruba, P D'Agostino, M Miele, M Calabro, C Barbera, G D Bella, S Milano, V Ferlazzo, R Caruso and M L Rosa: Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells. J Cell Biochem, 90 (1):187-196 (2003) (Pubitemid 37052320)
33. M L Salem: Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr Drug Targets Inflamm Allergy, 3 (1):97-104 (2004) (Pubitemid 38854894)
34. C Chavey, F Bibeau, S Gourgou-Bourgade, S Burlinchon, F Boissiere, D Laune, S Roques and G Lazennec: Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res, 9 (1):R15 (2007)
35. A Vazquez-Martin, R Colomer and J A Menendez: Her-2/neu-induced "cytokine signature" in breast cancer. Adv Exp Med Biol, 617:311-319 (2008)
36. T M Tuttle, B W Anderson, W E Thompson, J E Lee, A Sahin, T L Smith, K H Grabstein, J T Wharton, C G Ioannides and J L Murray: Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res, 4 (8):2015-2024 (1998) (Pubitemid 28369189)